

In the Claims

Please amend the claims as follows:

1. (Original) An isolated nucleic acid molecule encoding the protein cyplasin with a deleted or non-functional secretory signal sequence, being selected from the group consisting of
  - (a) a nucleic acid molecule encoding a protein comprising the amino acid sequence from position 20 or 53 to position 558 of the sequence marked with "L" of Figure 2(a) (SEQ ID NO: 1);
  - (b) a nucleic acid molecule comprising the sequence of Figure 2(b) (SEQ ID NO: 5);
  - (c) a nucleic acid molecule the nucleic acid sequence of which deviates from the nucleic sequences specified in (a) or (b) due to the degeneration of the genetic code; and
  - (d) a nucleic acid molecule, which represents a fragment, derivative or allelic variation of a nucleic acid sequence specified in (a), (b) or (c).
2. (Original) A recombinant vector containing a nucleic acid molecule of claim 1.
3. (Original) The recombinant vector of claim 2 wherein the nucleic acid molecule is operatively linked to regulatory elements allowing transcription and synthesis of a translatable RNA in prokaryotic and/or eukaryotic host cells.
4. (Currently amended) A recombinant host cell which contains the recombinant vector of claim 2 or 3.
5. (Original) The recombinant host cell of claim 4, which is a mammalian cell, a bacterial cell, an insect cell or a yeast cell.
6. (Original) An isolated protein encoded by the nucleic acid molecule of claim 1.
7. (Original) A method of making a protein exhibiting biological properties of cyplasin comprising:
  - (a) culturing the recombinant host cell of claim 4 under conditions such that said protein is expressed; and

- (b) recovering said protein.
8. (Currently amended) A method of making a cytotoxic protein in eukaryotic host cells which is cytotoxic for said cells when secreted from said cells or externally applied comprising:
- (a) culturing a host cell transfected with a nucleic acid sequence of claim 1 encoding said protein with a deleted or non-functional secretory signal sequence under conditions such that said protein is expressed; and
- (b) recovering said protein.
9. (Original) The method of claim 8 wherein the eukaryotic cells are mammalian cells.
10. (Currently amended) A pharmaceutical composition comprising a nucleic acid molecule of claim 1 ~~or a protein of claim 6~~.
11. (Currently amended) The pharmaceutical composition according to claim 10, wherein the composition is used ~~Use of a nucleic acid molecule of 1 or a protein of claim 6 for preparing a pharmaceutical composition for treating cancer.~~
12. (New) A pharmaceutical composition comprising a protein of claim 6.
13. (New) The pharmaceutical composition according to claim 12, wherein the composition is used for treating cancer.